60 results about "Internal bleeding" patented technology

Passive physiological monitoring apparatus and method has a sensor for sensing physiological phenomenon. A converter converts sensed data into electrical signals and a computer receives and computes the signals and outputs computed data for real-time interactive display. The sensor is a piezoelectric film of polyvinylidene fluoride. A band-pass filter filters out noise and isolates the signals to reflect data from the body. A pre-amplifier amplifies signals. Signals detected include mechanical, thermal and acoustic signatures reflecting cardiac output, cardiac function, internal bleeding, respiratory, pulse, apnea, and temperature. A pad may incorporate the PVDF film and may be fluid-filled. The film converts mechanical energy into analog voltage signals. Analog signals are fed through the band-pass filter and the amplifier. A converter converts the analog signals to digital signals. A Fourier transform routine is used to transform into the frequency domain. A microcomputer is used for recording, analyzing and displaying data for on-line assessment and for providing realtime response. A radio-frequency filter may be connected to a cable and the film for transferring signals from the film through the cable. The sensor may be an array provided in a MEDEVAC litter or other device for measuring acoustic and hydraulic signals from the body of a patient for field monitoring, hospital monitoring, transport monitoring, home, remote monitoring.

A detachable electrode and anchor utilized with electrode leads and leadless medical implants that enable explantation of the electrode while leaving the anchor in place. The detachable electrode and anchor utilizes a detachable mechanism that detachably couples the electrode to the anchor. Embodiments do not require removal of existing scar tissue before explantation, which minimize chances of internal bleeding at the extraction site. Embodiments also minimize impact on the vein in which the electrode lead travels by eliminating use of a necessarily larger diameter sheath that is utilized around the electrode lead to remove the electrode lead and attached anchor.

Passive physiological monitoring apparatus and method has a sensor for sensing physiological phenomenon. A converter converts sensed data into electrical signals and a computer receives and computes the signals and outputs computed data for real-time interactive display. The sensor is a piezoelectric film of polyvinylidene fluoride. Signals detected include mechanical, thermal and acoustic signatures reflecting cardiac output, cardiac function, internal bleeding, respiratory, pulse, apnea and temperature. The sensor may be an array (77) provided in a MEDEVAC litter (73) or other device for measuring acoustic and hydraulic signals from the body of a patient (63) for field monitoring, hospital monitoring, transport monitoring, home, remote monitoring.

A system is provided for detecting fluid accumulation in a subject. A movement induced by the beating of the heart is analyzed over time, by monitoring a movement, pressure or force. Changes in density caused by fluid accumulation result in changes in the sensor arrangement signals. Changes are used to indicate that fluid accumulation such as internal bleeding is likely to have taken place.

An endoscope or other medical device includes an elongated shaft having a flexible proximal section, an articulatable distal region, and distal tip. The endoscope or other device includes an associated hemostasis device for treating internal bleeding during a contemporaneous medial procedure. Embodiments of the present invention may incorporate mechanical, chemical, and / or electrical techniques for performing hemostasis.

The present invention encompasses a modified human urokinase plasminogen activator (“huPA”) gene, which was inserted in the adenoviral vector (pAd-.DELTA.huPA), which is not secreted and does not provoke hypercoagulation or spontaneous internal bleeding. It has been discovered that huPa induced a dramatic fibrosis reduction (85%) on day 10 of vector administration, compared to control cirrhotic rats and 55% hepatocyte proliferation increase. Liver function tests (ALT, AST, alkaline phosphatase and bilirubin) dropped to nearly normal levels and hepatocyte proliferation was observed. The invention also encompasses gene therapy with modified huPA to treat disorders in patients. In a particular embodiment, the invention encompasses a treatment for patients with liver cirrhosis.